Montelukast Zentiva (Montelukast Sodium)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 and related mediators from binding. This inhibition reduces bronchoconstriction, mucus production, vascular leakage, and inflammatory cell recruitment, leading to improved airway patency and symptom control.

The appropriate dose of Montelukast Zentiva is determined by the prescribing healthcare professional based on the patient’s age, weight, and specific condition. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Montelukast is classified as pregnancy category B, indicating no evidence of risk in animal studies but limited human data. It may be used during pregnancy only if clearly needed. Small amounts are excreted in breast milk; nursing mothers should discuss potential risks with their physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who prefer a once‑daily tablet, but it does not replace rescue inhalers for acute attacks.

Montelukast Zentiva tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources to maintain product stability.

Montelukast Zentiva is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the specific timing advised by their healthcare provider.

Serious risks include rare neuropsychiatric events such as depression, suicidal thoughts, and mood changes, as well as severe allergic reactions like rash, angioedema, or anaphylaxis. Liver enzyme elevations and blood dyscrasias have also been reported; any concerning symptoms should prompt immediate medical evaluation.

Montelukast is contraindicated in individuals with known hypersensitivity to montelukast sodium or any tablet excipients. It should not be used for acute asthma attacks, and patients with uncontrolled severe liver disease should avoid it unless specifically directed by a physician.